If you’ve been diagnosed with major depressive disorder, seasonal affective depression or any other type of depression, your ...

The largest, most ethnically diverse, study of its kind has flagged hundreds of genetic variants that play a role in ...

CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral ...

Johnson & Johnson has received FDA approval for Spravato nasal spray as the first and only monotherapy for adults with treatment-resistant depression.

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...

If you’ve been diagnosed with major depressive disorder or a form of anxiety, your mental health provider may prescribe the ...

Major depressive disorder (MDD) is a debilitating mental health condition characterized by persistent low mood, loss of ...

The U.S. Food and Drug Administration ( FDA) has approved the use of a nasal spray as a standalone treatment for major depressive disorder, offering a new option for those struggling with ...

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

A international joint research team of KAIST and the University of Michigan developed a digital biomarker for predicting ...